Ebola virus (EBOV;also known as Zaire ebolavirus) (family Filoviridae) is among the most lethal infectious agents known, producing sporadic outbreaks of severe, and highly lethal hemorrhagic fever in humans and nonhuman primates (NHPs). Owing to high morbidity and mortality rates in natural outbreaks, lack of prophylactic and treatment options, aerosol transmission potential, and their highly virulent nature, Ebola viruses have been identified as both NIAID Category A Priority pathogens and CDC Category A Agents of Bioterrorism. Despite this, the current standard of care is limited to palliative treatment and no therapeutic interventions have been approved against EBOV infection. Among many prophylactic and therapeutic platforms currently under development, monoclonal antibody (mAb) technology has emerged as one ofthe most promising treatment methods. Worldwide, there exist ~100 mAbs against EBOV that have been characterized to varying degrees. Six of these mAbs have demonstrated complete to partial protection of NHPs when administered from 1 to 4- 5 days after lethal infection. The goal of Project 1 is to achieve total protection in NHPs as late as possible in the course of infection with an

Public Health Relevance

This project will translate necessary post-exposure antibody cocktails against Ebola virus (Zaire): immediately from a small, fast-tracked antibody pool, and later from an unprecedented, field-wide, definitive analysis of a pool of almost all antibodies known against Ebola virus.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
1U19AI109762-01
Application #
8654208
Study Section
Special Emphasis Panel (ZAI1-LR-M (J1))
Project Start
2014-03-15
Project End
2019-02-28
Budget Start
2014-03-15
Budget End
2015-02-28
Support Year
1
Fiscal Year
2014
Total Cost
$1,159,802
Indirect Cost
$160,149
Name
Scripps Research Institute
Department
Type
DUNS #
781613492
City
La Jolla
State
CA
Country
United States
Zip Code
92037
Liu, Guodong; Wong, Gary; Su, Shuo et al. (2017) Clinical Evaluation of Ebola Virus Disease Therapeutics. Trends Mol Med 23:820-830
Wong, Gary; Mendoza, Emelissa J; Plummer, Francis A et al. (2017) From bench to almost bedside: the long road to a licensed Ebola virus vaccine. Expert Opin Biol Ther :1-15
Hofmann, Daniel; Lai, Jonathan R (2017) Exploring Human Antimicrobial Antibody Responses on a Single B Cell Level. Clin Vaccine Immunol 24:
Nyakatura, Elisabeth K; Soare, Alexandra Y; Lai, Jonathan R (2017) Bispecific antibodies for viral immunotherapy. Hum Vaccin Immunother 13:836-842
Zhao, Xuelian; Howell, Katie A; He, Shihua et al. (2017) Immunization-Elicited Broadly Protective Antibody Reveals Ebolavirus Fusion Loop as a Site of Vulnerability. Cell 169:891-904.e15
Mire, Chad E; Geisbert, Joan B; Borisevich, Viktoriya et al. (2017) Therapeutic treatment of Marburg and Ravn virus infection in nonhuman primates with a human monoclonal antibody. Sci Transl Med 9:
He, Jing; Melnik, Lilia I; Komin, Alexander et al. (2017) Ebola Virus Delta Peptide is a Viroporin. J Virol :
Fausther-Bovendo, H; Qiu, X; McCorrister, S et al. (2017) Ebola virus infection induces autoimmunity against dsDNA and HSP60. Sci Rep 7:42147
Wec, Anna Z; Herbert, Andrew S; Murin, Charles D et al. (2017) Antibodies from a Human Survivor Define Sites of Vulnerability for Broad Protection against Ebolaviruses. Cell 169:878-890.e15
Kroeker, Andrea; He, Shihua; de La Vega, Marc-Antoine et al. (2017) Characterization of Sudan Ebolavirus infection in ferrets. Oncotarget 8:46262-46272

Showing the most recent 10 out of 42 publications